Investment Summary

Istesso is a drug development company working in the field of immunometabolism. It’s pre-clinical and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune conditions. Istesso’s lead drug, MBS2320, is in a Phase 2a clinical trial in rheumatoid arthritis and has potential applications in other conditions such as ulcerative colitis and cancer. MBS2320 is partnered with Johnson & Johnson. Istesso raised a total of £6 million with the new capital enabling the business to expand MBS2320 into new indications and further develop its pre-clinical programmes. Parkwalk’s co-investors in the investment round were Puhua Capital, a Chinese venture capital firm with a strong presence in the healthcare sector, along with existing shareholder IP Group plc.